Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of ezetimibe and simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear cells: a randomized controlled study in healthy men

Trial Profile

Effects of ezetimibe and simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear cells: a randomized controlled study in healthy men

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary) ; Simvastatin (Primary)
  • Indications Cardiovascular disorders; Cystic fibrosis; Diabetic cardiomyopathy; Hypercholesterolaemia; Hyperlipoproteinaemia; Hypertriglyceridaemia; Low HDL cholesterol; Multiple sclerosis; Sitosterolaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Dec 2014 Status changed active, no longer recruiting to completed.
    • 01 Sep 2010 Results were reported at the ESC Congress 2010: Annual Congress of the European Society of Cardiology.
    • 01 May 2008 Results published in Atherosclerosis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top